Cytos Biotechnology AG and Pfizer Inc. Partner to Develop Immunodrugs for Animal Health

Strategic Insights -

Cytos Biotechnology AG, a Swiss biotechnology company, has entered into a research and commercial license option agreement with Pfizer Inc., a leading global pharmaceutical company. This partnership aims to develop immunodrugs for animal health applications, marking a significant milestone for Cytos Biotechnology in the animal health field. Under the agreement, Pfizer will have exclusive access to test two immunodrug candidates in its models, with the potential for exclusive development and commercial rights if the commercial license agreement is executed. In return, Cytos Biotechnology will receive an upfront payment and the opportunity to earn milestones and additional fees.

Key Takeaways:

  • Cytos Biotechnology AG has signed a research and commercial license option agreement with Pfizer Inc. for the testing of immunodrugs for animal health applications.
  • Pfizer gains exclusive access to test two Immunodrug candidates in its models and, if the commercial license agreement is executed, exclusive development and commercial rights to these two animal health product candidates.
  • Cytos Biotechnology will receive an upfront payment, and has the opportunity to earn milestones and additional fees on commercial license execution, on technology transfer for GMP manufacturing, on supply of drug substance, and on approval of Immunodrug candidates in major markets.
  • Cytos Biotechnology will earn royalties on Pfizer net sales if products are successfully launched.
  • Pfizer has the first claim to negotiate for any further Immunodrug candidates in the same therapeutic area, developed by Cytos Biotechnology for animal health.
  • The companies have negotiated terms for additional programs where Pfizer has the option to contribute its own proprietary disease antigens for other animal health disease indications.
  • Mark Dyer, executive vice president of business development at Cytos Biotechnology, commented on the partnership: "We are proud to announce this new deal with Pfizer, the world's premier animal healthcare company."
  • The collaboration builds on the success of Cytos Biotechnology's human healthcare programs and leverages Pfizer's expertise in development, regulatory, and commercial arenas.

Statistics:

  • Two Immunodrug candidates will be tested in Pfizer's models under the agreement.
  • Cytos Biotechnology will receive an upfront payment for the agreement.
  • The company has the opportunity to earn milestones and additional fees on commercial license execution, technology transfer for GMP manufacturing, supply of drug substance, and approval of Immunodrug candidates.
  • Cytos Biotechnology will earn royalties on Pfizer net sales if products are successfully launched.
  • The partnership marks Cytos Biotechnology's first deal in the animal health field, potentially extending the reach of its market opportunities beyond human healthcare.

Sources:

  • Health & Medicine Week editors
  • Cytos Biotechnology AG
  • Pfizer Inc.
  • NewsRx.com & NewsRx.net